Quest Diagnostics Incorporated $DGX Shares Bought by Keybank National Association OH

Keybank National Association OH raised its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 102.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,971 shares of the medical research company’s stock after buying an additional 7,054 shares during the period. Keybank National Association OH’s holdings in Quest Diagnostics were worth $2,510,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Quest Diagnostics in the first quarter valued at $1,228,000. First Horizon Advisors Inc. grew its stake in shares of Quest Diagnostics by 76.6% in the first quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company’s stock valued at $32,000 after buying an additional 82 shares in the last quarter. Brown Advisory Inc. grew its stake in shares of Quest Diagnostics by 2.2% in the first quarter. Brown Advisory Inc. now owns 7,081 shares of the medical research company’s stock valued at $1,198,000 after buying an additional 150 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Quest Diagnostics in the first quarter valued at $2,760,000. Finally, Fred Alger Management LLC grew its stake in shares of Quest Diagnostics by 9.9% in the first quarter. Fred Alger Management LLC now owns 19,378 shares of the medical research company’s stock valued at $3,279,000 after buying an additional 1,745 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Quest Diagnostics

In other news, Director Gary M. Pfeiffer sold 1,482 shares of the business’s stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $182.40, for a total value of $270,316.80. Following the completion of the sale, the director directly owned 29,431 shares of the company’s stock, valued at approximately $5,368,214.40. The trade was a 4.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael E. Prevoznik sold 28,288 shares of the business’s stock in a transaction dated Tuesday, September 23rd. The shares were sold at an average price of $187.12, for a total value of $5,293,250.56. Following the completion of the sale, the senior vice president directly owned 38,117 shares of the company’s stock, valued at $7,132,453.04. The trade was a 42.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 44,189 shares of company stock valued at $8,157,857. 8.16% of the stock is currently owned by corporate insiders.

Quest Diagnostics Trading Up 0.1%

NYSE:DGX opened at $175.93 on Friday. The stock has a 50-day simple moving average of $182.51 and a 200-day simple moving average of $177.40. The stock has a market cap of $19.57 billion, a P/E ratio of 20.65, a P/E/G ratio of 2.31 and a beta of 0.56. Quest Diagnostics Incorporated has a 1 year low of $148.70 and a 1 year high of $197.55. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, October 21st. The medical research company reported $2.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.09. The business had revenue of $2.82 billion during the quarter, compared to analysts’ expectations of $2.73 billion. Quest Diagnostics had a return on equity of 15.47% and a net margin of 8.91%.The business’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.30 EPS. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. As a group, analysts anticipate that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, October 20th. Stockholders of record on Friday, October 3rd were given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend was Friday, October 3rd. Quest Diagnostics’s dividend payout ratio is currently 37.56%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Truist Financial lifted their target price on Quest Diagnostics from $195.00 to $205.00 and gave the company a “hold” rating in a report on Wednesday, October 22nd. Morgan Stanley set a $207.00 target price on Quest Diagnostics and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Baird R W lowered Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 25th. Barclays lifted their target price on Quest Diagnostics from $190.00 to $195.00 and gave the company an “equal weight” rating in a report on Wednesday, October 22nd. Finally, Leerink Partners lifted their target price on Quest Diagnostics from $203.00 to $210.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $196.31.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.